Cargando…
Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
PURPOSE: To evaluate the safety and efficacy in intraocular pressure (IOP) reduction of increasing Cosopt dosage from twice to three times a day. METHODS: The study included patients with primary open-angle glaucoma or ocular hypertension. After a washout period, IOP was measured at baseline, after...
Autores principales: | Shemesh, Gabi, Moisseiev, Elad, Lazar, Moshe, Kurtz, Shimon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292411/ https://www.ncbi.nlm.nih.gov/pubmed/22393279 http://dx.doi.org/10.2147/OPTH.S30321 |
Ejemplares similares
-
Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily
por: Moisseiev, Elad, et al.
Publicado: (2013) -
A patient preference comparison of Azarga(™) (brinzolamide/timolol fixed combination) vs Cosopt(®) (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension
por: Mundorf, Thomas K, et al.
Publicado: (2008) -
Patient perspectives when switching from Cosopt(®) (dorzolamide-timolol) to Azarga™ (brinzolamide-timolol) for glaucoma requiring multiple drug therapy
por: Auger, Graham Anthony, et al.
Publicado: (2012) -
Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue, Kenji, et al.
Publicado: (2015) -
Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
por: Bell, Nicholas P, et al.
Publicado: (2010)